Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study to Assess the Efficacy and Safety of Omacor, Co-Administered With Open-Label Atorvastatin Therapy, in Hypertriglyceridemic Subjects
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Omacor (omega-3-acid ethyl esters) combined with atorvastatin for lowering non-high-density lipoprotein cholesterol (non-HDL-C) in hypertriglyceridemic subjects.


Options:
A: Arm Label: atorvastatin arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin | Arm Label: Lovaza arm; Type: EXPERIMENTAL; Interventions: Drug: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin | Intervention Type: DRUG; Name: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin; Assigned to Arm(s): Lovaza arm | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): atorvastatin arm
B: Intervention Type: DRUG; Name: Atorvastatin (Lipitor); Assigned to Arm(s): N/A
C: Arm Label: simvastatin/ezetimibe (vytorin) group; Type: EXPERIMENTAL; Interventions: Drug: simvastatin/ezetimibe | Arm Label: atorvastatin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin 20mg | Intervention Type: DRUG; Name: simvastatin/ezetimibe; Assigned to Arm(s): simvastatin/ezetimibe (vytorin) group | Intervention Type: DRUG; Name: atorvastatin 20mg; Assigned to Arm(s): atorvastatin group
D: Arm Label: 30 milligram (mg) LY2484595 monotherapy; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Placebo for Statins | Arm Label: 100 mg LY2484595 monotherapy; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Placebo for Statins | Arm Label: 500 mg LY2484595 monotherapy; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Placebo for Statins | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for LY2484595, Drug: Placebo for Statins | Arm Label: 20 mg Atorvastatin monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo for LY2484595 | Arm Label: 100 mg LY2484595 + 20 mg Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Atorvastatin | Arm Label: 40 mg Simvastatin monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo for LY2484595 | Arm Label: 100 mg LY2484595 + 40 mg Simvastatin; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Simvastatin | Arm Label: 10 mg Rosuvastatin monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Placebo for LY2484595 | Arm Label: 100 mg LY2484595 + 10 mg Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Rosuvastatin | Intervention Type: DRUG; Name: LY2484595; Assigned to Arm(s): 100 mg LY2484595 + 10 mg Rosuvastatin, 100 mg LY2484595 + 20 mg Atorvastatin, 100 mg LY2484595 + 40 mg Simvastatin, 100 mg LY2484595 monotherapy, 30 milligram (mg) LY2484595 monotherapy, 500 mg LY2484595 monotherapy | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 100 mg LY2484595 + 20 mg Atorvastatin, 20 mg Atorvastatin monotherapy | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 100 mg LY2484595 + 40 mg Simvastatin, 40 mg Simvastatin monotherapy | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 10 mg Rosuvastatin monotherapy, 100 mg LY2484595 + 10 mg Rosuvastatin | Intervention Type: DRUG; Name: Placebo for LY2484595; Assigned to Arm(s): 10 mg Rosuvastatin monotherapy, 20 mg Atorvastatin monotherapy, 40 mg Simvastatin monotherapy, Placebo | Intervention Type: DRUG; Name: Placebo for Statins; Assigned to Arm(s): 100 mg LY2484595 monotherapy, 30 milligram (mg) LY2484595 monotherapy, 500 mg LY2484595 monotherapy, Placebo

Answer: A